Development Focus - The company is focused on developing Adrulipase, a biologic for treating exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis patients[210] - The company discontinued the Latiglutenase, Capeserod, and Niclosamide programs, indicating a strategic shift in its development focus[210] - The company plans to move the Adrulipase program forward in 2026 after positive safety data from a Phase 2b study[218] - The company has focused its research and development expenses on Adrulipase, Niclosamide, Capeserod, and Latiglutenase, expecting these expenses to increase in the foreseeable future[250] - The company is evaluating potential asset acquisitions and business combinations to expand its product pipeline[243] Financial Performance - As of September 30, 2025, the company had cash and cash equivalents of approximately $2.5 million and cumulative losses attributable to common stockholders of approximately $3.7 million[240] - The company has not generated any revenue to date and anticipates continuing net losses for the foreseeable future[240][249] - The net loss for the three months ended September 30, 2025 totaled approximately $1,152,809, a decrease of approximately $1,428,162, or 55%, compared to a net loss of approximately $2,580,971 for the same period in 2024[265] - The net loss for the nine months ended September 30, 2025 totaled approximately $3,410,700, a decrease of approximately $2,410,367, or 41%, compared to a net loss of approximately $5,821,067 for the same period in 2024[275] - Cash used in operating activities for the nine months ended September 30, 2025 was approximately $1,729,201, a significant improvement compared to $9,046,305 for the same period in 2024[276] Compliance and Regulatory Matters - The company received a 180-day extension from Nasdaq until September 1, 2025, to regain compliance with the minimum bid price requirement of $1.00 per share[225] - The company has been granted an extension until June 30, 2025, to regain compliance with Nasdaq Listing Rule 5620(a) after holding its Annual Meeting[227] Mergers and Acquisitions - On September 30, 2025, the company acquired Grid AI Corp., purchasing 424,348 shares of common stock and 38,801,546 shares of Series H Non-Voting Convertible Preferred Stock[211] - The company announced a merger with ImmunogenX, Inc. in March 2024, but has since initiated a plan to dispose of certain assets, including Latiglutenase and CypCel[212] - The company expects to close the Rescission Agreement with IMGX by November 30, 2025, which will result in IMGX no longer being a subsidiary[214] Expenses and Financing - The company entered into a Revolving Loan Agreement with a principal amount of $2.0 million, with an initial loan disbursement of $700,000 and an interest rate of 18% per annum[245] - The accumulated interest on the Revolving Note as of September 30, 2025, was approximately $79,500[245] - The company is actively pursuing a Qualified Public Equity Offering (QPEO) of not less than $5 million[245] - General and administrative expenses for the three months ended September 30, 2025 totaled approximately $928,114, a decrease of approximately $757,494, or 45%, compared to $1,685,608 for the same period in 2024[256] - General and administrative expenses for the nine months ended September 30, 2025 totaled approximately $2,362,957, a decrease of approximately $11,172,284, or 83%, compared to $13,535,241 for the same period in 2024[266] - Research and development expenses for the three months ended September 30, 2025 totaled approximately $6,673, a decrease of approximately $200,326, or 97%, compared to $206,999 for the same period in 2024[256] - For the nine months ended September 30, 2025, research and development expenses totaled approximately $32,080, a decrease of approximately $850,442, or 96%, compared to $882,522 for the same period in 2024[266] - Net cash provided by financing activities for the nine months ended September 30, 2025 was approximately $3,725,000, compared to $5,613,152 for the same period in 2024[280] Future Outlook - The company has not yet achieved profitability and may never do so, raising substantial doubt about its ability to continue as a going concern[240][242] - The company plans to incur substantial expenditures for the development of Adrulipase and will require additional financing for clinical trials and regulatory approvals[242] - The company expects research and development expenses to increase during the remainder of the fiscal year[258] - Cash provided by investing activities for the nine months ended September 30, 2025 was $336,427, attributed to the Grid AI acquisition, compared to $0 in 2024[279]

BOCA RATON, FLORIDA / ACCESS Newswire / November 19, 2025 / Entero Therapeutics, Inc. (NASDAQ:ENTO) ("Entero" or the "Company") today announced that its subsidiary Grid AI has executed a Letter of Intent (LOI) with a stealth-mode hyperscaler artificial intelligence (AI) data-center developer to deploy Grid AI's advanced power-cluster optimization and orchestration platform at the customer's first large-scale AI campus. The campus-expected to be among the more sophisticated AI-ready digital-infrastructure si ...

Group 1 - The article highlights a significant acceleration in AI-data-center expansion, with over $60 billion in new projects announced in the last 90 days [1] - Entero Therapeutics, Inc. announced that its subsidiary, Grid AI, is in the process of establishing a leadership team in the U.S. [1] - The leadership team will consist of highly accomplished executives from the energy, power, and technology sectors [1]

Core Insights - Entero Therapeutics, Inc. announced the signing of a Letter of Intent to integrate the LV Grid engineering team and related intellectual property into Grid AI, which is seen as a critical step in enhancing Grid AI's capabilities in the AI data-center energy-orchestration market [1] Company Developments - The integration of LV Grid is expected to significantly boost Grid AI's deployment capacity as the demand for AI data-center power approaches 50 GW, with a projected growth of over 165% through 2030 [1]

Core Insights - Entero Therapeutics, Inc. has launched Grid AI Corp. to innovate the connection between artificial intelligence infrastructure and the power grid [1] - The company highlights that the rapid growth of artificial intelligence is leading to the fastest infrastructure development in modern history, with power supply becoming a critical bottleneck [1] Company Developments - The establishment of Grid AI Corp. signifies Entero Therapeutics' commitment to redefining AI infrastructure [1] - The focus on AI-driven energy infrastructure indicates a strategic move to address emerging challenges in power supply related to AI advancements [1] Industry Trends - The rise of artificial intelligence is creating unprecedented demands on infrastructure, particularly in the energy sector [1] - The current landscape suggests that power supply issues may hinder further advancements in AI technology and its applications [1]

Core Insights - Entero Therapeutics has transformed its business model by acquiring GRID AI, positioning itself in a critical sector focused on meeting the energy demands of artificial intelligence [1] Company Summary - The acquisition of GRID AI marks a significant strategic shift for Entero Therapeutics, allowing the company to engage directly in the energy sector, which is increasingly vital for supporting AI technologies [1] Industry Summary - The race to ensure energy supply keeps pace with the growing needs of artificial intelligence is identified as one of the most urgent challenges of the decade, highlighting the importance of innovations in energy solutions [1]

Core Viewpoint - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - Concorde International Group Ltd. (CIGL) increased by 53% to $3.94 [3] - Fermi Inc. Common Stock (FRMI) rose by 13% to $36.99 [3] - Kodiak AI, Inc. (KDK) also saw a 13% increase, reaching $6.76 [3] - AngioDynamics, Inc. (ANGO) gained 12%, trading at $12.45 [3] - Angel Studios, Inc. (ANGX) was up 11% at $8.51 [3] - Spruce Biosciences, Inc. (SPRB) increased by 9% to $9.75 [3] - K Wave Media Ltd. (KWM) rose by 9% to $2.66 [3] - Shoals Technologies Group, Inc. (SHLS) saw an 8% increase, trading at $8.59 [3] - StableX Technologies, Inc. (SBLX) was up 7% at $5.65 [3] Premarket Losers - Uni-Fuels Holdings Limited (UFG) decreased by 51% to $2.42 [4] - Akanda Corp. (AKAN) fell by 13% to $2.91 [4] - Equifax Inc. (EFX) dropped 11%, trading at $224.57 [4] - TransUnion (TRU) also saw an 11% decline, reaching $73.24 [4] - Bolt Biotherapeutics, Inc. (BOLT) decreased by 11% to $4.99 [4] - Dogwood Therapeutics, Inc. (DWTX) fell by 8% to $6.50 [4] - Galaxy Payroll Group Limited (GLXG) decreased by 8% to $4.52 [4] - Old Market Capital Corporation (OMCC) dropped 7% to $5.08 [4] - Entero Therapeutics, Inc. (ENTO) fell by 7% to $3.96 [4] - Flux Power Holdings, Inc. (FLUX) decreased by 7% to $3.74 [4]

Market Overview - U.S. stock futures showed mixed performance following record advances on Wednesday, with Dow Jones futures down 0.04%, S&P 500 futures up 0.17%, Nasdaq 100 futures up 0.36%, and Russell 2000 futures up 0.41% [3] - The Dow Jones index closed 43 points higher at 46,441.10, S&P 500 rose 0.34% to 6,711.20, Nasdaq Composite advanced 0.42% to 22,755.16, and Russell 2000 gained 0.24% to 2,442.35 [7][8] Economic Impact of Government Shutdown - The Trump administration warned that a government shutdown could reduce weekly GDP by $15 billion and increase unemployment by 43,000 if it lasts a month [1] - The Senate rejected funding bills from both parties, with the next voting opportunity scheduled for Friday [2] - The shutdown coincides with a critical economic moment, as the ADP report indicated a surprising drop of 32,000 jobs in the private sector, missing forecasts of a gain of over 50,000 [6] Analyst Insights - Brian Rehling from Wells Fargo suggests that the potential government shutdown will likely have a negligible long-term impact on the economy and markets, despite causing short-term volatility [10] - Rehling notes that the biggest market impact would be the delay of key economic reports, which could cloud the Federal Reserve's outlook for rate cuts [11] - Rehling anticipates that any market pullback could present an opportunity for investors to reposition their portfolios [12] Sector Performance - Gains were observed in Health Care and Utilities sectors, while Materials and Financials experienced losses, indicating a mixed sector performance [4] - Wells Fargo rates Financials, Information Technology, and Industrials as favorable sectors for investment, alongside Utilities due to the growth in data centers related to artificial intelligence [17] Stocks in Focus - AngioDynamics, Inc. saw a premarket jump of 6.14% ahead of its earnings report, while Entero Therapeutics Inc. dropped 6.76% after its acquisition of GRID AI Corp [21] - Gulf Island Fabrication Inc. climbed 9.25% after securing a $35 million contract, and Concorde International Group Ltd. surged 55.25% following the approval of a 2025 Equity Incentive Plan [21]

Group 1 - AngioDynamics, Inc. (NASDAQ:ANGO) is expected to report a quarterly loss of 12 cents per share on revenue of $72.72 million [2] - Grindr Inc (NYSE:GRND) appointed John North as chief financial officer, effective immediately [2] - Entero Therapeutics (NASDAQ:ENTO) acquired 100% of GRID AI Corp [2] - Gulf Island Fabrication Inc (NASDAQ:GIFI) received a $35 million fabrication contract for the Francis Scott Key Bridge project in Baltimore, Maryland [2] - Globant SA (NYSE:GLOB) approved a share repurchase program of up to $125 million [2]

Core Insights - Entero Therapeutics, Inc. has acquired 100% of GRID AI Corp, positioning the company in the high-growth AI energy-infrastructure market [1] - The acquisition comes amid a surge in multi-billion-dollar spending by hyperscalers on data centers and rapid growth in behind-the-meter energy storage solutions [1] Company Overview - GRID AI is a grid-edge, AI-driven software and device platform that allows utilities, retailers, and large power users to manage load and distributed energy resources dynamically [1] - Over $50 million has been invested in GRID AI since 2019 to commercialize its autonomous platform [1] Technology and Innovation - The platform delivers Dynamic Load Shaping™ (DLS) and an Aggregation Management Platform (AMP) [1] - It orchestrates millions of behind-the-meter assets, including EV chargers, batteries, HVAC systems, water heaters, and rooftop solar, using AI, machine learning, and edge analytics [1] Market Impact - The technology aims to balance supply and demand in real-time, contributing to a more reliable, resilient, and transactive grid [1]